Coronary Artery Disease Clinical Trial
Official title:
Fractional Flow Reserve-Guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment Versus Optimal Medical Treatment Alone in Patients With Stable Coronary Artery Disease
NCT number | NCT01132495 |
Other study ID # | 0904 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 2010 |
Est. completion date | May 2015 |
Verified date | August 2019 |
Source | Abbott Medical Devices |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The overall purpose of the FAME II trial is to compare the clinical outcomes, safety and cost-effectiveness of FFR-guided PCI plus optimal medical treatment (OMT) versus OMT alone in patients with stable coronary artery disease.
Status | Completed |
Enrollment | 1170 |
Est. completion date | May 2015 |
Est. primary completion date | January 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: 1. Patients with - stable angina or, - stabilized angina pectoris or, - atypical chest pain or no chest pain but with documented silent ischemia 2. at least one stenosis is present of at least 50% in one major native epicardial coronary artery and supplying viable myocardium 3. Eligible for PCI 4. Signed written informed consent Exclusion Criteria: 1. Patients in whom the preferred treatment is CABG 2. Patients with left main coronary artery disease requiring revascularization 3. Patients with a recent STEMI or Non-STEMI 4. Prior CABG 5. Contra-indication to dual antiplatelet therapy 6. LVEF < 30% 7. Severe LV hypertrophy 8. Planned need for concomitant cardiac surgery 9. Extremely tortuous or calcified coronary arteries precluding FFR measurements 10. A life expectancy of less than 2 years 11. Age under 21 |
Country | Name | City | State |
---|---|---|---|
Belgium | OLV Ziekenhuis | Aalst | |
Canada | Centre Hospitalier de l'Universite de Montreal | Montreal | Quebec |
Canada | Hopital du Sacre-Coeur de Montreal | Montreal | Quebec |
Czechia | Masaryk University and University Hospital Brno | Brno | |
Czechia | Na Homolce Hospital | Praha | |
Denmark | Rigshospitalet University Hospital | Copenhagen | |
France | Hospices Civils de Lyon | Bron | |
Germany | Heart Center Leipzig | Leipzig | |
Germany | Klinikum der Universitat Munchen | Munchen | |
Germany | Stadtisches Klinikum Munchen | Munchen | |
Hungary | Gottsegen Hungarian Institute of Cardiology | Budapest | |
Italy | Azienda Ospedaliero Universitaria de Ferrara | Ferrara | |
Netherlands | Catharina-Ziekenhuis | Eindhoven | |
Netherlands | St. Antonius Ziekenhuis | Nieuwegein | |
Netherlands | Isala Klinieken | Zwolle | |
Serbia | Clinical Center Kragujevac | Kragujevac | |
Sweden | Orebro University Hospital | Orebro | |
Sweden | Sodersjukhuset AB | Stockholm | |
United Kingdom | Royal Victoria Hospital | Belfast | |
United Kingdom | Edinburgh Heart Centre | Edinburgh | |
United Kingdom | Golden Jubilee National Hospital | Glasgow | |
United Kingdom | Kings College Hospital | London | |
United Kingdom | Southampton University Hospitals NHS | Southampton | |
United States | Emory University | Atlanta | Georgia |
United States | Northeast Cardiology Associates | Bangor | Maine |
United States | Atlanta VA Medical Center | Decatur | Georgia |
United States | Tulane University | New Orleans | Louisiana |
United States | VA Palo Alto | Palo Alto | California |
United States | Stanford University Medical Center | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Abbott Medical Devices |
United States, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Serbia, Sweden, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Major Adverse Cardiac Event Rate (MACE) | MACE: A composite of all cause death, documented MI, unplanned hospitalization leading to urgent revascularization. | 24 Month | |
Secondary | Overall MACE | Individual components of the primary end point, cardiac death, and nonurgent revascularization | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |